mRNA-LNP Stability: The Engineering Challenge Behind RNA Therapeutics

Introduction

Following the success of COVID-19 vaccines, mRNA technology has rapidly emerged as one of the most important platforms in modern biotechnology.

By enabling human cells to temporarily produce therapeutic proteins, mRNA therapeutics are being explored across a wide range of medical applications, including:

• Vaccines

• Cancer immunotherapy

• Protein replacement therapies

• Gene editing (CRISPR delivery)

However, mRNA molecules are inherently fragile.

Without protection, mRNA can degrade rapidly in biological environments. As a result, nearly all mRNA therapeutics rely on a critical delivery technology:

Lipid nanoparticles (LNPs).

These nanoscale particles encapsulate RNA and enable safe delivery into cells.

Yet this powerful delivery system also introduces a major challenge:

mRNA-LNP stability.

A recent study systematically analyzed how formulation conditions and storage environments affect the long-term stability of mRNA-LNP drug products, revealing key factors that determine the shelf life of RNA medicines.

The Structure of mRNA Lipid Nanoparticles

To understand the challenges of mRNA-LNP stability, it is important to first examine the structure of this delivery system.

A typical mRNA-LNP formulation contains four major lipid components:

Ionizable lipid

This lipid binds RNA and facilitates endosomal escape after cellular uptake.

Helper lipid (DSPC)

Provides structural stability to the lipid membrane.

Cholesterol

Enhances nanoparticle rigidity and membrane integrity.

PEG-lipid

Improves particle stability and reduces immune recognition.

During microfluidic mixing, these lipids self-assemble with mRNA to form nanoscale particles.

However, these nanoparticles are not rigid structures. Instead, they are dynamic assemblies stabilized by weak molecular interactions, making them sensitive to environmental conditions.

Why Are mRNA-LNPs Unstable?

The instability of mRNA-LNP systems arises from several interconnected mechanisms.

1. Chemical Instability of mRNA

mRNA is inherently unstable and can degrade through several pathways, including:

• Ribose backbone cleavage

• Nucleobase oxidation

• Hydrolysis

• 5′ cap degradation

Even under refrigerated conditions, these degradation reactions can occur gradually.

2. Lipid Oxidation

Ionizable lipids within LNPs can also undergo oxidation.

For example, the commonly used lipid DLin-MC3-DMA (MC3) may form oxidized species such as MC3 N-oxide.

These oxidized lipids can generate reactive aldehydes that interact with RNA, forming mRNA-lipid adducts and reducing RNA functionality.

3. Nanoparticle Structural Changes

Because LNPs are self-assembled lipid structures, they are sensitive to physical stress.

Common structural changes include:

• Particle fusion

• Nanoparticle aggregation

• RNA leakage

These changes can significantly reduce transfection efficiency.

Temperature Is the Most Important Stability Factor

Storage temperature is one of the most critical factors affecting mRNA-LNP stability.

Researchers evaluated four storage conditions:

• −80°C

• −20°C

• 5°C

• 25°C

The results clearly demonstrate how temperature influences nanoparticle stability.

−80°C

Nearly all quality attributes remain stable:

• mRNA purity

• Nanoparticle morphology

• Transfection activity

Minimal changes are observed even after 12 months of storage.

−20°C

Moderate stability is maintained, although early signs of aggregation appear.

5°C

Under refrigerated conditions:

• mRNA purity decreases

• Nanoparticle concentration declines

• Transfection efficiency drops

After 12 months, expression activity may decrease by nearly tenfold.

25°C

At room temperature, degradation occurs rapidly.

Within six months, transfection activity is nearly completely lost.

Cold Chain Logistics and mRNA Vaccines

The stability of mRNA-LNP formulations has direct implications for global vaccine distribution.

During the early rollout of COVID-19 vaccines:

• The Pfizer-BioNTech vaccine required storage around −70°C

• The Moderna vaccine required −20°C storage

These stringent cold chain requirements created significant logistical challenges for global vaccination campaigns.

Improving mRNA-LNP stability is therefore not only a pharmaceutical challenge but also a major public health priority.

Lipid Chemistry Also Influences Stability

Different ionizable lipids exhibit different stability profiles.

Studies comparing DLin-MC3-DMA and ALC-0315 (used in Pfizer’s vaccine) show that:

ALC-0315 demonstrates improved resistance to oxidation.

MC3-based formulations tend to generate more oxidized lipid species, including:

• MC3 N-oxide

• Reactive lipid intermediates

These by-products can accelerate RNA degradation.

This highlights how lipid chemical structure plays a critical role in determining mRNA-LNP stability.

The Role of Buffers and Cryoprotectants

Formulation buffers are another important factor in maintaining nanoparticle stability.

One commonly used formulation includes:

20 mM Tris buffer + 10% sucrose

Sucrose acts as a cryoprotectant, protecting nanoparticles during freezing.

However, buffer composition also affects RNA chemistry.

Higher Tris concentrations can accelerate 5′ cap hydrolysis, which reduces mRNA translation efficiency.

Therefore, low-ionic-strength buffers are generally preferred for RNA formulations.

Future Directions for RNA Delivery Technologies

Researchers are exploring multiple strategies to improve the stability of RNA medicines.

These include:

Next-generation ionizable lipids

Including biodegradable and oxidation-resistant lipid designs.

Lyophilized LNP formulations

Freeze-drying technologies may significantly extend shelf life.

Alternative nanoparticle architectures

Such as polymer-lipid hybrid systems.

Improved mRNA engineering

Including modified nucleotides and optimized cap structures.

Together, these innovations may enable future RNA therapeutics to be stored at refrigerated or even room temperatures.

Conclusion

The success of mRNA vaccines has demonstrated the transformative potential of RNA therapeutics.

However, the true engineering challenge lies not in the RNA itself but in the delivery system.

mRNA-LNP formulations represent highly complex nanomedicine platforms involving:

• Lipid chemistry

• RNA stability

• Nanoparticle physics

• Formulation science

Understanding and improving mRNA-LNP stability will be essential for the next generation of RNA therapeutics.

As new delivery technologies and lipid designs emerge, we may soon see RNA medicines that are easier to store, distribute, and deploy globally.

FAQ

Why do mRNA vaccines require ultra-cold storage?

mRNA molecules are chemically unstable and susceptible to degradation through hydrolysis and oxidation. Ultra-cold temperatures slow these reactions and preserve nanoparticle integrity.

What are lipid nanoparticles (LNPs)?

Lipid nanoparticles are nanoscale drug delivery systems composed of ionizable lipids, helper lipids, cholesterol, and PEG-lipids that encapsulate RNA and deliver it into cells.

What factors determine mRNA-LNP stability?

Major factors include:

• Storage temperature

• Lipid composition

• Buffer formulation

• Cryoprotectants

Can mRNA drugs eventually be stored at room temperature?

Researchers are actively developing new lipid chemistries, freeze-dried formulations, and improved RNA designs that may enable room-temperature storage in the future.

About LuTra Studio

LuTra Studio is a biotechnology knowledge platform founded by a Taiwanese scientist working in the U.S. biotech industry.

The platform focuses on translating complex scientific concepts into accessible insights covering:

• RNA therapeutics

• Lipid nanoparticle delivery systems

• Gene therapy platforms

• Biotechnology innovation and industry trends

In addition to publishing educational content, LuTra Studio also provides technical consulting for biotechnology startups and research teams, helping organizations evaluate emerging therapeutic technologies and development strategies.

🌐 Learn more https://www.lutrastudio.studio

References

Nomani et al. 2026, Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability, Nanomaterials 

Hou et al., 2021, Lipid nanoparticles for mRNA delivery, Nature Reviews Materials

Cullis & Hope, 2017, Lipid nanoparticle systems for enabling gene therapies, Molecular Therapy

Schoenmaker et al., 2021, mRNA-lipid nanoparticle COVID-19 vaccines, International Journal of Pharmaceutics

Pardi et al., 2018, mRNA vaccines — a new era in vaccinology, Nature Reviews Drug Discovery

Kulkarni et al., 2018, On the formation and morphology of lipid nanoparticles, Nano Letters